Caspase-1 Inhibitors Using Extended Tethering Technology

Information

  • Research Project
  • 6644037
  • ApplicationId
    6644037
  • Core Project Number
    R43AR049976
  • Full Project Number
    1R43AR049976-01
  • Serial Number
    49976
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 21 years ago
  • Project End Date
    1/31/2004 - 21 years ago
  • Program Officer Name
    TYREE, BERNADETTE
  • Budget Start Date
    8/1/2003 - 21 years ago
  • Budget End Date
    1/31/2004 - 21 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/28/2003 - 21 years ago

Caspase-1 Inhibitors Using Extended Tethering Technology

[unreadable] DESCRIPTION (provided by applicant): The long-term objective of this proposal is to apply a unique and powerful "extended tethering" technology to discover novel therapeutics for the treatment of arthritis. Small molecule caspase-1 inhibitors represent a new class of arthritis therapeutics with the advantages of oral availability and decreased toxicity. Covalent tethering technology involves discovering drug-like fragments that bind to a target protein and assembling them into potent inhibitors. A protein containing a cysteine residue near a site of interest is screened against a library of sulfhydryl-containing fragments to identify fragments that bind and form a disulfide bond. In "extended tethering," the selected fragments are modified to irreversibly bind to the cysteine residue and to contain a new sulfhydryl group. These "extended tethers" allow further selection from the fragment library for additional nearby binding fragments that form a disulfide bond with the extended tether. We propose to generate and then screen five caspase-1/extended tether complexes with our fragment library to identify nearby binding fragments. Reversibly binding versions of the extended tether coupled to the selected companion fragment will be used to generate potent non-disulfide containing inhibitors. Extended tethering provides an efficient means of ligand discovery and a direct path to lead optimization since the target protein is used as a template for the construction of its own inhibitor. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SUNESIS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94080
  • Organization District
    UNITED STATES